View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Mar. 17, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Central Index Key	0001211583
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 10,156,736
Trading Symbol	FENCF
Entity Common Stock, Shares Outstanding		13,642,567

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,926	$ 942
Prepaid expenses	43	76
Other current assets	3	1
Total assets	3,972	1,019
Current liabilities:
Accounts payable	244	297
Accrued liabilities	125	92
Derivative instruments (Note 5)	33	82
Total current liabilities	402	471
Total liabilities	402	471
Commitments and Contingencies (Note 9)
Shareholders' equity:
Common stock, no par value; unlimited shares authorized; 13,643 shares issued and outstanding (2015-10,940)	74,515	69,401
Additional paid-in capital	42,134	41,437
Accumulated deficit	(114,322)	(111,533)
Accumulated other comprehensive income	1,243	1,243
Total shareholders’ equity	3,570	548
Total liabilities and shareholders’ equity	$ 3,972	$ 1,019

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2016	Dec. 31, 2015
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	13,643	10,940
Common stock, shares outstanding	13,643	10,940

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 0	$ 0
Operating expenses:
Research and development	472	256
General and administrative	2,399	1,634
Loss from operations	(2,871)	(1,890)
Other income/(expense):
Unrealized gain on derivatives (Note 5)	48	1,237
Sale of Eniluracil (Note 8)	40	0
Other loss	(14)	(9)
Net interest income	8	3
Total other income, net	82	1,231
Net loss	$ (2,789)	$ (659)
Loss per common share, basic and diluted	$ (0.22)	$ (0.06)
Weighted-average number of common shares outstanding, basic (Note 3)	12,765	10,827

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net (loss)	$ (2,789)	$ (659)
Adjustments to reconcile net (loss) to net cash used in operating activities:
Unrealized gain on derivatives	(48)	(1,237)
Stock-based compensation - consultants	88	0
Stock-based compensation - employees	615	97
Changes in operating assets and liabilities:
Prepaid expenses	33	(28)
Other assets	(2)	16
Accounts payable	(54)	(11)
Accrued liabilities	33	(40)
Net cash used in operating activities	(2,124)	(1,862)
Investing activity:
Net cash used in investing activity	0	0
Financing activities:
Issuance of shares, net of issuance costs	5,000	0
Issuance of shares, options exercise	6	48
Issuance of shares, warrants exercise	102	449
Net cash provided by financing activities	5,108	497
Effect of exchange rate on cash and cash equivalents	0	0
(Decrease) increase in cash and cash equivalents	2,984	(1,365)
Cash and cash equivalents - Beginning of year	942	2,307
Cash and cash equivalents - End of year	$ 3,926	$ 942

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2014	$ 613	$ 68,656	$ 41,588	$ 1,243	$ (110,874)
Balance (in shares) at Dec. 31, 2014		10,593
Stock options issued	97	$ 0	97	0	0
Exercise of stock options	48	$ 82	(34)	0	0
Exercise of stock options (in shares)		47
Exercise of warrants	449	$ 663	(214)	0	0
Exercise of warrants (in shares)		300
Net loss	(659)	$ 0	0	0	(659)
Balance at Dec. 31, 2015	548	$ 69,401	41,437	1,243	(111,533)
Balance (in shares) at Dec. 31, 2015		10,940
Stock options issued \| Consultants [Member]	16	$ 0	16	0	0
Stock options issued \| Employees [Member]	615	0	615	0	0
Warrants issued to consultants	72	0	72	0	0
Exercise of stock options	6	$ 6	0	0	0
Exercise of stock options (in shares)		4
Exercise of warrants	102	$ 108	(6)	0	0
Exercise of warrants (in shares)		67
Rights offering	5,000	$ 5,000	0	0	0
Rights offering (in shares)		2,632
Net loss	(2,789)	$ 0	0	0	(2,789)
Balance at Dec. 31, 2016	$ 3,570	$ 74,515	$ 42,134	$ 1,243	$ (114,322)
Balance (in shares) at Dec. 31, 2016		13,643

Nature of Business and Going Concern

12 Months Ended

Dec. 31, 2016

Going Concern [Abstract]

Nature of Business and Going Concern

1.	Nature of Business and Going Concern

Fennec Pharmaceuticals Inc. (“Fennec”) was originally formed as a British Columbia corporation under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a biopharmaceutical company with a product candidate under development for use in the treatment of cancer. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

During the year ended December 31, 2016 the Company incurred a net loss from operations of $2,871 and still has not earned any revenue in its history. At December 31, 2016, it had an accumulated deficit of $114,322 and had experienced negative cash flows from operating activities in the amount of $2,124.

These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issue date of these consolidated financial statements, and substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company is actively seeking to obtain additional funding in the future in order to finance the Company’s business strategy, operations and growth through the issuance of equity, debt or collaboration. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing.

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Prior-period adjustment

Common Stock at December 31, 2015 has been increased by $248 and Additional Paid-in Capital has been decreased by the same amount, to retrospectively correct balance sheet amounts with respect to an immaterial noncash error related to the exercise of warrants and stock options. This error was the result of not moving the value in Additional Paid-in Capital to Common Stock when the warrants and stock options were exercised. This adjustment does not impact anything other than the allocation between Common Stock and Additional Paid-in Capital and has no effect on our loss per share disclosures.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Significant Accounting Policies [Abstract]

Significant Accounting Policies

2.	Significant Accounting Policies

Basis of presentation

The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.

Use of estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2016, the Company had $3,926 in cash and money market accounts (2015- $942). Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments.

Financial instruments

Financial instruments recognized on the balance sheets at December 31, 2016 and December 31, 2015 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative instruments, the carrying values of which, with the exception of the derivative instruments, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value.

The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.

The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trading or speculative nature.

Common stock and warrants

The Company has warrants outstanding to purchase common stock that were denominated in both United States dollars (“USD”) and Canadian dollars (“CAD”), which resulted in the Company having warrants outstanding that were denominated outside of the Company’s U.S. dollar functional currency.

The Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to the Company’s own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. At December 31, 2016, the derivative liabilities were valued at $33 (2015-$82). There was an unrealized gain on derivative liabilities of $48 (2015-$1,237) for the year ended December 31, 2016.

Revenue recognition

At this time, the Company does not have any revenue.

Research and development costs and investment tax credits

Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.

Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.

Income taxes

The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December 31, 2016, we maintained a full valuation allowance against our deferred tax assets.

The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.

Foreign currency translation

The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations.

Loss per share

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number of shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Accordingly, options to purchase 2,427 and warrants to purchase 1,383 shares at December 31, 2016, were not included in earnings per share. These options and warrants were not included in the computation of diluted earnings per share because the exercise prices were greater than the average market price of the common shares during the period, and accordingly, such options and warrants would have an antidilutive effect. In 2015, options to purchase 2,417 and warrants to purchase 2,595 shares were excluded from the computation of earnings per share because the exercise prices were greater than the average market price of the common shares and accordingly, their inclusion would have been antidilutive.

Recent accounting pronouncements

In August 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-15 requiring an entity’s management to evaluate whether there are conditions or events, considered in aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of this standard did not have a material impact on our financial statements.

In June 2014, the FASB issued ASU 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amended guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The adoption of this standard did not have a material impact on our financial statements.

In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. The Company does not believe adoption of this guidance will have a material impact on its financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2020, although early adoption is permitted. The impact of the Company’s current lease is not material to the financial statements. Currently, this standard is not expected to impact the Company.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends the accounting for share-based payment transactions. These changes, which are designed for simplification, involve several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2018, although early adoption is permitted. The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

Loss per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share

Loss per Share

Loss per common share is presented under two formats: basic loss per common share and diluted loss per common share. Basic loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common stock equivalents (e.g. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data):

	Twelve Months Ended
	December 31, 2016		December 31, 2015
Numerator:
Net loss	$	(2,789)	$	(659)

Denominator:
Weighted-average common shares, basic		12,765		10,827
Dilutive effect of stock options		-		-
Dilutive effect of warrants		-		-
Incremental dilutive shares		-		-
Weighted-average common shares, dilutive		12,765		10,827
Net loss per share, basic and diluted	$	(0.22)	$	(0.06)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

	Twelve Months Ended
	December 31, 2016		December 31, 2015
Options to purchase common stock		2,427		2,417
Warrants to purchase common stock		1,383		2,595

Stock options

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options

Stock options

The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the stock option plan from a fixed number of 6,666 to the number of shares that represents twenty-five percent (25%) of the total number of all issued and outstanding shares of common stock. Based upon the current shares outstanding, a maximum of 3,410 options are authorized for issuance under the plan. The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years⁽¹⁾ from the date of grant. The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2016 is below.

(1)

On April 25, 2014 Fennec granted 133 options each to Dr. Khalid Islam and Adrian Haigh. Such options shall vest: (i) as to 66 Common Shares, on the date of grant; and (ii) as to 67 Common Shares, upon and subject to orphan drug approval of STS in the EU, provided that they then remain on the Board of Directors of the Company at the time of such approval and that they have played a vital or precipitating part in obtaining such EU orphan drug designation, as reasonably determined by non-interested Board members. If the vesting conditions referred to in (ii) above have not occurred by May 31, 2016, the option to acquire the 66 Common Shares referred to in (ii) above shall be terminated and of no further force or effect. On November 7, 2014 the Board of Directors amended the vesting conditions. The Board determined that it would be appropriate and desirable to amend the conditions such that (i) it could be fully satisfied by the Company obtaining, in lieu of orphan drug designation, PUMA in Europe for STS; and (ii) the deadline for satisfaction of the vesting condition extended to December 31, 2017. The Company has not recognized any expense associated with these options. On the date vesting conditions are met, the Company will recognize all of the expense associated with these options.

Summary of $CAD Option Activity

	Number of				Weighted
Share Prices Reported in $CAD	Options		Range		Average
Outstanding and exercisable at December 31, 2014		1,338	$	1.62 – 2.43	$	2.38
Exercised		(14)		1.62 – 2.43		1.94
Forfeited or expired		(1)		1.62 – 2.43		1.82
Outstanding and exercisable at December 31, 2015		1,323	$	1.62 – 2.43	$	2.39
Exercised		(-)		-		-
Forfeited or expired		(324)		2.43		2.43
Outstanding and exercisable at December 31, 2016		999	$	1.62 – 2.43	$	2.38

Summary of $CAD Option Remaining Life

Price $CAD		Outstanding and Exercisable at December 31, 2016		Weighted Average Remaining Life (years)
$	1.62		17		1.26
$	1.89		76		1.39
$	2.43		906		1.35
	Total		999		1.35

Summary of $USD Option Activity

	Number of				Weighted
	Options		Range		Average
Outstanding and exercisable at December 31, 2014		1,072	$	0.45 – 15.66	$	1.77
Granted		71		1.13 – 2.51		1.36
Exercised		(33)		0.60 – 1.05		0.83
Forfeited or expired		(16)		0.54 – 15.66		2.24
Outstanding and exercisable at December 31, 2015		1,094	$	0.45 – 3.60	$	1.77
Granted		370		2.11 – 2.45		2.42
Exercised		(4)		1.50		1.50
Forfeited or expired		(32)		1.89 - 2.69		2.65
Outstanding and exercisable at December 31, 2016		1,428	$	0.45 – 3.60	$	1.93

Summary of $USD Option Remaining Life

		Number Outstanding
Price in		and Exercisable at		Remaining Life
US Dollars		December 31, 2016		(years)
$	0.45		11		2.63
$	0.54		19		3.38
$	0.60		58		2.54
$	0.72		83		3.40
$	0.96		11		3.03
$	1.05		113		2.97
$	1.13		50		5.95
$	1.23		8		4.15
$	1.50		16		2.31
$	1.59		176		4.04
$	1.68		33		2.97
$	1.89		8		1.63
$	2.11		36		7.00
$	2.30		4		3.90
$	2.31		275		4.29
$	2.35		4		4.01
$	2.40		8		2.85
$	2.44		49		6.11
$	2.45		285		6.51
$	2.51		4		3.82
$	2.55		4		3.65
$	2.69		118		4.78
$	2.79		49		4.59
$	2.94		3		2.91
$	3.60		3		3.40
	Total		1,428		4.59

Stock compensation expense for the fiscal years ended December 31, 2016 and 2015 was $615 and $97 respectively. These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2016 and 2015 was $2.42 and $1.37, respectively. The intrinsic value (being the difference between the share price at December 31, 2016 and exercise price) of stock options exercisable at December 31, 2016 was $575. The intrinsic value of options exercised during the fiscal year ended December 31, 2016 was $3. The fair value of all options vested during the fiscal year ended December 31, 2016 was $280.

The fair values of options granted in fiscal years ended December 31, 2016 and 2015 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions for all options with a seven year expiration:

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
Expected dividend		0	%		0	%
Risk-free interest rate		1.27 – 2.25	%		1.89 – 2.02	%
Expected volatility		134 – 137	%		127 – 153	%
Expected life		7 years			7 years

The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price.

Modification of Existing US Dollar Denominated Options

In 2016, the Company modified the terms of certain options granted to executives and directors by extending the expiration date by 1 year. The Company recorded option modification expense of approximately $4 included in general and administrative expense. The expense was calculated using the Black-Scholes valuation method. The following table summarizes the effect of the June 8, 2016 transaction:

															Expense
Number of		Expiration	Risk Free			Exercise		Share Price		Expected					Recognized
Options		Date	Rate			Price $USD		$USD		Life (Years)		Volatility			$USD
	6	11/18/2018		0.93	%		1.50		2.43		3.44		152	%		1
	17	04/04/2020		1.08	%		0.60		2.43		3.82		155	%		1
	19	05/17/2020		1.08	%		0.54		2.43		3.94		154	%		1
	9	11/20/2020		1.08	%		1.05		2.43		4.45		147	%		1
	51															4

Modification of Existing Canadian Dollar Denominated Options

In 2016, the Company modified the terms of certain options granted to executives and directors by extending the expiration date by a weighted average amount of 1.45 years. The Company recorded option modification expense of approximately $347 included in general and administrative expense. The expense was calculated using the Black-Scholes valuation method with a June 8, 2016 exchange rate of $CAD/$USD 0.7881. The following table summarizes the effect of the June 8, 2016 transaction:

															Expense
Number of		Expiration	Risk Free			Exercise		Share Price		Expected					Recognized
Options		Date	Rate			Price $CAD		$CAD		Life (Years)		Volatility			$USD
	17	08/18/2018		0.52	%		1.89		3.10		2.19		94	%		9
	648	08/18/2018		0.52	%		2.43		3.10		2.19		94	%		338
	665															347

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Derivative Liabilities

12 Months Ended

Dec. 31, 2016

Derivative Instruments [Abstract]

Derivative Liabilities

Derivative Liabilities

The Company's derivative instruments include options to purchase 40 common shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

⋅

Contractor options to purchase 21 common shares exercisable at CAD$1.89 per whole common share that expire on November 19, 2017;

⋅

Contractor options to purchase 17 common shares exercisable at CAD$1.62 per whole common share that expire on April 4, 2018;

⋅

Contractor options to purchase 2 common shares exercisable at CAD$2.43 per whole common share that expire on May 18, 2018.

These options have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These options will continue to be reported as a liability until such time as they are exercised, forfeited or expire. The fair value of these options is estimated using the Black-Scholes option-pricing model.

Options issued to contractors in a foreign currency

During the fiscal years ended December 31, 2011 and 2010, the Company issued 36 and 29 (respectively) options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of Denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. All Canadian denominated options issued to contractors fully vest at issuance and expire seven years from date of issuance. The fair value of these options at December 31, 2016 and December 31, 2015 was $33 and $41, respectively. The gain for these options for the twelve months ended December, 2016 was $7. There was a gain on these options for the twelve months ended December, 2015 of $78.

The following is a summary of Canadian denominated contractor option activity for the twelve months ended December 31, 2016 and 2015.

Share Prices Reported in $CAD	Number of Options
	Outstanding and		Weighted Average
	Exercisable		Exercise Price
Outstanding and exercisable at December 31, 2014		55	$	1.84
Exercised		(14)		1.94
Forfeited or expired		(1)		1.82
Outstanding and exercisable at December 31, 2015		40	$	1.81
Exercised		-		-
Forfeited or expired		-		-
Outstanding and exercisable at December 31, 2016		40	$	1.81

The following table presents the overall change in derivative liability for the twelve months ended December 31, 2016 and December 31, 2015:

	Derivative Value at				Gain/(Loss) on Derivative
Derivative Warrants/Options	December 31,				Instrument December 31,
	2016		2015		2016		2015
Warrants expired April 30, 2015		-		-		-		411
Warrants expiring March 29, 2016		-		41		41		748
Options (various expiration dates)		33		41		7		78
Total		33		82		48		1,237

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

6.	Fair Value Measurements

The Company has adopted ASC 820 Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Assets/Liabilities Measured at Fair Value on a Recurring Basis

Fair Value Measurement at December 31, 2016

Quoted Price in Active

Market for Identical

Significant Other

Significant

Instruments

Observable Inputs

Unobservable Inputs

Level 1

Level 2

Level 3

Total

Assets

Cash and cash equivalents

⁽¹⁾

3,858

3,926

Liabilities

Derivative liabilities

The Company's financial instruments include cash and cash equivalents and derivative liabilities. Only cash and cash equivalents and derivative liabilities are carried at their fair value. The derivative liabilities are options issued to contractors in a currency other than the functional currency of the Company. The options use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 0.33 – 0.74%; expected volatility of 57%- 85%; and a 0.9-1.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument or for a minimum of six months if the remaining life is less than six months.

(1)

The Company held $68 in cash, of which $51 was in Canadian funds (translated into U.S. dollars).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.

Equity financings

On May 16, 2016, the Company completed the closing of a non-brokered private placement (the “Offering”) of 2,631,579 units for gross proceeds of $5,000 to Essetifin, SpA. Each unit was issued at a price of $1.90 per unit and each unit consisted of 1 common share of the Company.

Warrants to Purchase Common Stock

At December 31, 2016, the Company had the following warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $1.55 and a weighted average remaining life of 1.9 years:

	Common Shares Issuable Upon
Warrant	Exercise of Outstanding		Exercise Price
Description	Warrants at December 31, 2016		CAD/USD		Expiration Date
Investor warrants⁽¹⁾		1,333	$	1.50 USD	November 22, 2018
Investor warrants⁽²⁾		50	$	3.00 USD	February 2, 2019
		1,383

(1)

On November 22, 2013, the Company announced it had completed the closing of a non-brokered private placement of 4,000 units, at a price of $0.40 per unit for net proceeds of $1,600. Each unit consisted of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share of the Company at a price of $0.50 per share for a period of five years from the date of issuance. As a result of the September 3, 2014 share consolidation, each three (3) warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of $1.50 per whole share for a period of five years from the issue date.

(2)

On February 2, 2016 the company issued 50 warrants to Aranea Partners in lieu of cash for investor services. These warrants are fully vested at December 31, 2016 and are redeemable for $3.00 per common share. The fair value of these warrants is estimated using the Black-Scholes pricing model.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Sale of Asset

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]

Sale of Asset

Sale of Asset

On August 29, 2016, Fennec completed the sale of certain intellectual property, data and other assets related to Eniluracil and Adh-1 technologies and development programs to Elion Oncology, LLC for gross proceeds of $40. The Company retained the rights to revenue share payments of 5% of the gross revenues derived from the sold assets until the last to expire patents forming part of such assets.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Commitments and Contingencies

Oregon Health & Science University Agreement

On February 20, 2013, Fennec entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology.

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 ("OHSU Agreement") to include the use of N-acetylcysteine as a standalone therapy and/or in combination with STS for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product.

The term of Amendment 1 under the OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

Executive Severance

In the event of his termination with us other than for cause, the Company will pay its Chief Executive Officer, Rostislav Raykov, a one-time severance compensation payment equal to 12 months of salary (currently $250). Further, the Company will pay Chief Financial Officer, Robert Andrade, a one-time severance compensation equal to 6 months salary (currently $95).

De-recognition of Statute Barred Payables

12 Months Ended

Dec. 31, 2016

De-recognition of Statute Barred Payables [Abstract]

De-recognition of Statute Barred Payables

10.

De-recognition of Statute Barred Payables

The Company had various payables from obligations which existed before current management took over the Company in 2009. These payables, although previously recorded, could not be substantiated as legitimate payables by management. Approximately $79 worth of these payables became statute barred and were therefore written off in 2016 by reversing the original expense entry. This caused the reversal of approximately $23 of general and administrative expense and approximately $56 of research and development expense in the current year. These amounts are presented net in the general and administrative and research and development figures in financial statements.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

11.

Income Taxes

The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
Domestic (loss)/gain		(1,771)			294
Foreign loss		(1,018)			(952)
Loss before income taxes		(2,789)			(658)

Expected statutory rate (recovery)		26.50	%		26.50	%
Expected provision for (recovery of) income tax		(739)			(174)
Permanent differences		156			(301)
Change in valuation allowance		583			(1,297)
Effect of foreign exchange rate differences		-			-
Effect of non-capital losses expired		-			1,318
Tax credits and other adjustments		1			450
Effect of tax rate changes and other		-1			4
Provision for income taxes	$	-		$	-

The Canadian statutory come tax rate of 26.0 percent is comprised of federal income tax at approximately 15.0 percent and provincial income tax at approximately 11.0 percent.

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2016, December 31, 2015:

	December 31,		December 31,
	2016		2015
Future tax assets:
SR&ED expenditures		2,195		2,195
Income tax loss carryforwards		19,098		18,509
Non-refundable investment tax credits		1,263		1,263
Share issue costs		4		10
Accrued expenses		-		-
Fixed and intangible assets		1,032		1,032
Harmonization credit		-		-
		23,592		23,010
Less: valuation allowance		(23,592)		(23,010)
Net future tax assets	$	-	$	-

There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. At December 31, 2016 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry-forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below:

			Province/
	Federal		State
SR&ED expenditures (no expiry)	$	8,283	$	-
Income tax loss carryforwards (expiry date):
2021		26		-
2022		233		-
2023		133		-
2024		1,536		1,455
2025		4,795		4,768
2026		20,562		12,945
2027		8,340		10,866
2028		10,840		10,550
2029		8,502		3,915
2030		2,608		3,243
2031		3,378		3,675
2032		3,491		1,754
2033		1,788		1,781
2034		1,812		1,684
2035		1,803		2,150
2036		2,222		1,013
Investment tax credits (expiry date):
2018		10
2019		8
2020		96
2021		55
2022		548
2023		399
2024		178
2025		199
2026		86
2027		90
2028		50
2029		-
2030		-

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Significant Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

The consolidated financial statements include the accounts of Fennec and of all its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.

Use of estimates

Use of estimates

Cash and cash equivalents

Cash and Cash Equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.

Financial instruments

Financial instruments

Common stock and warrants

Common stock and warrants

Revenue recognition

Revenue recognition

At this time, the Company does not have any revenue.

Research and development costs and investment tax credits

Research and development costs and investment tax credits

Income taxes

Income taxes

Foreign currency translation

Foreign currency translation

The U.S. dollar is the functional currency for the Company’s consolidated operations. All gains and losses from currency translations are included in results of operations.

Earnings/(Loss) per share

Loss per share

New Accounting Pronouncements Adopted

Recent accounting pronouncements

Loss per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share (in thousands except per share data):

	Twelve Months Ended
	December 31, 2016		December 31, 2015
Numerator:
Net loss	$	(2,789)	$	(659)

Denominator:
Weighted-average common shares, basic		12,765		10,827
Dilutive effect of stock options		-		-
Dilutive effect of warrants		-		-
Incremental dilutive shares		-		-
Weighted-average common shares, dilutive		12,765		10,827
Net loss per share, basic and diluted	$	(0.22)	$	(0.06)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Twelve Months Ended
	December 31, 2016		December 31, 2015
Options to purchase common stock		2,427		2,417
Warrants to purchase common stock		1,383		2,595

Stock options (Tables)

12 Months Ended

Dec. 31, 2016

Fair values of options granted using weighted average assumptions

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
Expected dividend		0	%		0	%
Risk-free interest rate		1.27 – 2.25	%		1.89 – 2.02	%
Expected volatility		134 – 137	%		127 – 153	%
Expected life		7 years			7 years

Currency, Canadian Dollar [Member]

Options granted under the stock option plan are exercisable

Summary of $CAD Option Activity

	Number of				Weighted
Share Prices Reported in $CAD	Options		Range		Average
Outstanding and exercisable at December 31, 2014		1,338	$	1.62 – 2.43	$	2.38
Exercised		(14)		1.62 – 2.43		1.94
Forfeited or expired		(1)		1.62 – 2.43		1.82
Outstanding and exercisable at December 31, 2015		1,323	$	1.62 – 2.43	$	2.39
Exercised		(-)		-		-
Forfeited or expired		(324)		2.43		2.43
Outstanding and exercisable at December 31, 2016		999	$	1.62 – 2.43	$	2.38

Options reinstated agreement either expired and cancelled prior to the agreed severance

Summary of $CAD Option Remaining Life

Price $CAD		Outstanding and Exercisable at December 31, 2016		Weighted Average Remaining Life (years)
$	1.62		17		1.26
$	1.89		76		1.39
$	2.43		906		1.35
	Total		999		1.35

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the effect of the June 8, 2016 transaction:

															Expense
Number of		Expiration	Risk Free			Exercise		Share Price		Expected					Recognized
Options		Date	Rate			Price $CAD		$CAD		Life (Years)		Volatility			$USD
	17	08/18/2018		0.52	%		1.89		3.10		2.19		94	%		9
	648	08/18/2018		0.52	%		2.43		3.10		2.19		94	%		338
	665															347

Currency, U.S. Dollar [Member]

Options granted under the stock option plan are exercisable

Summary of $USD Option Activity

	Number of				Weighted
	Options		Range		Average
Outstanding and exercisable at December 31, 2014		1,072	$	0.45 – 15.66	$	1.77
Granted		71		1.13 – 2.51		1.36
Exercised		(33)		0.60 – 1.05		0.83
Forfeited or expired		(16)		0.54 – 15.66		2.24
Outstanding and exercisable at December 31, 2015		1,094	$	0.45 – 3.60	$	1.77
Granted		370		2.11 – 2.45		2.42
Exercised		(4)		1.50		1.50
Forfeited or expired		(32)		1.89 - 2.69		2.65
Outstanding and exercisable at December 31, 2016		1,428	$	0.45 – 3.60	$	1.93

Options reinstated agreement either expired and cancelled prior to the agreed severance

Summary of $USD Option Remaining Life

		Number Outstanding
Price in		and Exercisable at		Remaining Life
US Dollars		December 31, 2016		(years)
$	0.45		11		2.63
$	0.54		19		3.38
$	0.60		58		2.54
$	0.72		83		3.40
$	0.96		11		3.03
$	1.05		113		2.97
$	1.13		50		5.95
$	1.23		8		4.15
$	1.50		16		2.31
$	1.59		176		4.04
$	1.68		33		2.97
$	1.89		8		1.63
$	2.11		36		7.00
$	2.30		4		3.90
$	2.31		275		4.29
$	2.35		4		4.01
$	2.40		8		2.85
$	2.44		49		6.11
$	2.45		285		6.51
$	2.51		4		3.82
$	2.55		4		3.65
$	2.69		118		4.78
$	2.79		49		4.59
$	2.94		3		2.91
$	3.60		3		3.40
	Total		1,428		4.59

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the effect of the June 8, 2016 transaction:

															Expense
Number of		Expiration	Risk Free			Exercise		Share Price		Expected					Recognized
Options		Date	Rate			Price $USD		$USD		Life (Years)		Volatility			$USD
	6	11/18/2018		0.93	%		1.50		2.43		3.44		152	%		1
	17	04/04/2020		1.08	%		0.60		2.43		3.82		155	%		1
	19	05/17/2020		1.08	%		0.54		2.43		3.94		154	%		1
	9	11/20/2020		1.08	%		1.05		2.43		4.45		147	%		1
	51															4

Derivative Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Derivative Instruments [Abstract]

Schedule of Other Share-based Compensation, Activity

The following is a summary of Canadian denominated contractor option activity for the twelve months ended December 31, 2016 and 2015.

Share Prices Reported in $CAD	Number of Options
	Outstanding and		Weighted Average
	Exercisable		Exercise Price
Outstanding and exercisable at December 31, 2014		55	$	1.84
Exercised		(14)		1.94
Forfeited or expired		(1)		1.82
Outstanding and exercisable at December 31, 2015		40	$	1.81
Exercised		-		-
Forfeited or expired		-		-
Outstanding and exercisable at December 31, 2016		40	$	1.81

Derivative Liabilities Fair Value

The following table presents the overall change in derivative liability for the twelve months ended December 31, 2016 and December 31, 2015:

	Derivative Value at				Gain/(Loss) on Derivative
Derivative Warrants/Options	December 31,				Instrument December 31,
	2016		2015		2016		2015
Warrants expired April 30, 2015		-		-		-		411
Warrants expiring March 29, 2016		-		41		41		748
Options (various expiration dates)		33		41		7		78
Total		33		82		48		1,237

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Assets/Liabilities Measured at Fair Value on Recurring Basis

Assets/Liabilities Measured at Fair Value on a Recurring Basis

	Fair Value Measurement at December 31, 2016
	Quoted Price in Active Market for Identical Instruments			Significant Other Observable Inputs		Significant Unobservable Inputs
	Level 1			Level 2		Level 3		Total
Assets
Cash and cash equivalents	$	68	⁽¹⁾	$	3,858	$	-	$	3,926
Liabilities
Derivative liabilities		-			33				33

(1)

The Company held $68 in cash, of which $51 was in Canadian funds (translated into U.S. dollars).

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity [Abstract]

Warrants Outstanding to Purchase Common Stock

	Common Shares Issuable Upon
Warrant	Exercise of Outstanding		Exercise Price
Description	Warrants at December 31, 2016		CAD/USD		Expiration Date
Investor warrants⁽¹⁾		1,333	$	1.50 USD	November 22, 2018
Investor warrants⁽²⁾		50	$	3.00 USD	February 2, 2019
		1,383

(1)

(2)

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
Domestic (loss)/gain		(1,771)			294
Foreign loss		(1,018)			(952)
Loss before income taxes		(2,789)			(658)

Expected statutory rate (recovery)		26.50	%		26.50	%
Expected provision for (recovery of) income tax		(739)			(174)
Permanent differences		156			(301)
Change in valuation allowance		583			(1,297)
Effect of foreign exchange rate differences		-			-
Effect of non-capital losses expired		-			1,318
Tax credits and other adjustments		1			450
Effect of tax rate changes and other		-1			4
Provision for income taxes	$	-		$	-

Summary of Tax Credit Carryforwards

The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2016, December 31, 2015:

	December 31,		December 31,
	2016		2015
Future tax assets:
SR&ED expenditures		2,195		2,195
Income tax loss carryforwards		19,098		18,509
Non-refundable investment tax credits		1,263		1,263
Share issue costs		4		10
Accrued expenses		-		-
Fixed and intangible assets		1,032		1,032
Harmonization credit		-		-
		23,592		23,010
Less: valuation allowance		(23,592)		(23,010)
Net future tax assets	$	-	$	-

			Province/
	Federal		State
SR&ED expenditures (no expiry)	$	8,283	$	-
Income tax loss carryforwards (expiry date):
2021		26		-
2022		233		-
2023		133		-
2024		1,536		1,455
2025		4,795		4,768
2026		20,562		12,945
2027		8,340		10,866
2028		10,840		10,550
2029		8,502		3,915
2030		2,608		3,243
2031		3,378		3,675
2032		3,491		1,754
2033		1,788		1,781
2034		1,812		1,684
2035		1,803		2,150
2036		2,222		1,013
Investment tax credits (expiry date):
2018		10
2019		8
2020		96
2021		55
2022		548
2023		399
2024		178
2025		199
2026		86
2027		90
2028		50
2029		-
2030		-

Nature of Business and Going Concern - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Going Concern [Line Items]
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (2,124)	$ (1,862)
Retained Earnings (Accumulated Deficit)	(114,322)	(111,533)
Operating Income (Loss)	$ (2,871)	(1,890)
Increase In Common Stock Value		$ 248

Significant Accounting Policies - Additional Information (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 3,926	$ 942
Derivative Liability (Note 3)	33	82
Unrealized (loss)/gain on derivatives	$ 48	$ 1,237
Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,383	2,595
Stock Option [Member]
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,427	2,417

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details

Loss per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net loss	$ (2,789)	$ (659)
Denominator:
Weighted-average common shares, basic	12,765	10,827
Incremental dilutive shares	0	0
Weighted-average common shares, dilutive	12,765	10,827
Net loss per share, basic and diluted	$ (0.22)	$ (0.06)
Warrant [Member]
Denominator:
Incremental dilutive shares	0	0
Employee Stock Option [Member]
Denominator:
Incremental dilutive shares	0	0

Loss per Share (warrants were excluded from the computation of basic and diluted net loss per share) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,427	2,417
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,383	2,595

Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares shares	Dec. 31, 2016 $ / shares shares	Dec. 31, 2015 $ / shares shares	Dec. 31, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding and Exercisable at Ending \| shares	1,428,000	1,428,000
Stock Option In Canadian Dollars [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding and Exercisable at Beginning \| shares	1,323,000	1,323,000	1,338,000	1,338,000
Number of Options Exercised \| shares	0	0	(14,000)	(14,000)
Number of Options Forfeited or expired \| shares	(324,000)	(324,000)	(1,000)	(1,000)
Number of Options Outstanding and Exercisable at Ending \| shares	999,000	999,000	1,323,000	1,323,000
Exercised Range		$ 0
Forfeited or expired Range		2.43
Weighted-average Exercise Price Outstanding and Exercisable at Beginning		2.39		$ 2.38
Weighted- average Exercised		0		1.94
Weighted- average Forfeited or expired		2.43		1.82
Weighted-average Exercise Price Outstanding and Exercisable at Ending		2.38		2.39
Stock Option In Canadian Dollars [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding and Exercisable Range		1.62		2.43
Exercised Range				2.43
Forfeited or expired Range				2.43
Outstanding and Exercisable Range		2.43		1.62
Stock Option In Canadian Dollars [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding and Exercisable Range				1.62
Exercised Range				1.62
Forfeited or expired Range				$ 1.62
Outstanding and Exercisable Range		$ 1.62
Stock Option In Us Dollars [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding and Exercisable at Beginning \| shares	1,094,000	1,094,000	1,072,000	1,072,000
Number of Options Granted \| shares	370,000	370,000	71,000	71,000
Number of Options Exercised \| shares	(4,000)	(4,000)	(33,000)	(33,000)
Number of Options Forfeited or expired \| shares	(32,000)	(32,000)	(16,000)	(16,000)
Number of Options Outstanding and Exercisable at Ending \| shares	1,428,000	1,428,000	1,094,000	1,094,000
Exercised Range	$ 1.50
Weighted-average Exercise Price Outstanding and Exercisable at Beginning	1.77		$ 1.77
Weighted- average Granted	2.42		1.36
Weighted- average Exercised	1.50		0.83
Weighted- average Forfeited or expired	2.65		2.24
Weighted-average Exercise Price Outstanding and Exercisable at Ending	1.93		1.77
Stock Option In Us Dollars [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding and Exercisable Range	3.60		15.66
Granted Range	2.45		2.51
Exercised Range			1.05
Forfeited or expired Range	2.69		15.66
Outstanding and Exercisable Range	3.60		$ 3.60
Stock Option In Us Dollars [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Granted \| shares			1,130	1,130
Outstanding and Exercisable Range	0.45		$ 0.45
Granted Range	2.11		1.13
Exercised Range			0.60
Forfeited or expired Range	1.89		0.54
Outstanding and Exercisable Range	$ 0.45		$ 0.45

Stock options (Price In Canadian Dollars) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding and Exercisable	1,428
Weighted average remaining life (years)	4 years 7 months 2 days
Currency Canadian Dollar [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding and Exercisable	999
Weighted average remaining life (years)	1 year 4 months 6 days
Price In Canadian Dollars 1.62 [Member] \| Currency Canadian Dollar [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.62
Number Outstanding and Exercisable	17
Weighted average remaining life (years)	1 year 3 months 4 days
Price In Canadian Dollars 1.89 [Member] \| Currency Canadian Dollar [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.89
Number Outstanding and Exercisable	76
Weighted average remaining life (years)	1 year 4 months 20 days
Price In Canadian Dollars 2.43 [Member] \| Currency Canadian Dollar [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.43
Number Outstanding and Exercisable	906
Weighted average remaining life (years)	1 year 4 months 6 days

Stock Options (Price In US Dollars) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Number Outstanding and Exercisable	1,428
Remaining life (years)	4 years 7 months 2 days
Price In Us Dollars 0.45 [Member]
Number Outstanding and Exercisable	11
Remaining life (years)	2 years 7 months 17 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 0.45
Price In Us Dollars 0.54 [Member]
Number Outstanding and Exercisable	19
Remaining life (years)	3 years 4 months 17 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 0.54
Price In Us Dollars 0.60 [Member]
Number Outstanding and Exercisable	58
Remaining life (years)	2 years 6 months 14 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 0.60
Price In Us Dollars 0.72 [Member]
Number Outstanding and Exercisable	83
Remaining life (years)	3 years 4 months 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 0.72
Price In Us Dollars 0.96 [Member]
Number Outstanding and Exercisable	11
Remaining life (years)	3 years 11 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 0.96
Price In Us Dollars 1.05 [Member]
Number Outstanding and Exercisable	113
Remaining life (years)	2 years 11 months 19 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.05
Price In Us Dollars 1.13[Member]
Number Outstanding and Exercisable	50
Remaining life (years)	5 years 11 months 12 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.13
Price In Us Dollars 1.23 [Member]
Number Outstanding and Exercisable	8
Remaining life (years)	4 years 1 month 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.23
Price In Us Dollars 1.50 [Member]
Number Outstanding and Exercisable	16
Remaining life (years)	2 years 3 months 22 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.50
Price In Us Dollars 1.59 [Member]
Number Outstanding and Exercisable	176
Remaining life (years)	4 years 14 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.59
Price In Us Dollars 1.68 [Member]
Number Outstanding and Exercisable	33
Remaining life (years)	2 years 11 months 19 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.68
Price In Us Dollars 1.89 [Member]
Number Outstanding and Exercisable	8
Remaining life (years)	1 year 7 months 17 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 1.89
Price In Us Dollars 2.11 [Member]
Number Outstanding and Exercisable	36
Remaining life (years)	7 years
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.11
Price In Us Dollars 2.30 [Member]
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 10 months 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.30
Price In Us Dollars 2.31 [Member]
Number Outstanding and Exercisable	275
Remaining life (years)	4 years 3 months 14 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.31
Price In Us Dollars 2.35 [Member]
Number Outstanding and Exercisable	4
Remaining life (years)	4 years 4 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.35
Price In Us Dollars 2.40 [Member]
Number Outstanding and Exercisable	8
Remaining life (years)	2 years 10 months 6 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.40
Price In Us Dollars 2.44 [Member]
Number Outstanding and Exercisable	49
Remaining life (years)	6 years 1 month 10 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.44
Price In Us Dollars 2.45 [Member]
Number Outstanding and Exercisable	285
Remaining life (years)	6 years 6 months 4 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.45
Price In Us Dollars 2.51 [Member]
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 9 months 25 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.51
Price In Us Dollars 2.55 [Member]
Number Outstanding and Exercisable	4
Remaining life (years)	3 years 7 months 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.55
Price In Us Dollars 2.69 [Member]
Number Outstanding and Exercisable	118
Remaining life (years)	4 years 9 months 11 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.69
Price In Us Dollars 2.79 [Member]
Number Outstanding and Exercisable	49
Remaining life (years)	4 years 7 months 2 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.79
Price In Us Dollars 2.94 [Member]
Number Outstanding and Exercisable	3
Remaining life (years)	2 years 10 months 28 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 2.94
Price In Us Dollars 3.60 [Member]
Number Outstanding and Exercisable	3
Remaining life (years)	3 years 4 months 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price \| $ / shares	$ 3.60

Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Expected dividend	0.00%	0.00%
Expected life	7 years	7 years
Maximum [Member]
Risk-free interest rate	2.25%	2.02%
Expected volatility	137.00%	153.00%
Minimum [Member]
Risk-free interest rate	1.27%	1.89%
Expected volatility	134.00%	127.00%

Stock options (Modification of Existing US Dollar Denominated Options) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years	7 years
Share Based Compensation	$ 615	$ 97
Executives and Directors [Member] \| U.S.dollars [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	51
Share Based Compensation	$ 4
Executives and Directors [Member] \| U.S.dollars [Member] \| Stock Option Grant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	6
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 18, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.93%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.50
Share Price	$ 2.43
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 5 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	152.00%
Share Based Compensation	$ 1
Executives and Directors [Member] \| U.S.dollars [Member] \| Stock Option Grant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	17
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Apr. 04, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.60
Share Price	$ 2.43
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 9 months 25 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	155.00%
Share Based Compensation	$ 1
Executives and Directors [Member] \| U.S.dollars [Member] \| Stock Option Grant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	19
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	May 17, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.54
Share Price	$ 2.43
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 11 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	154.00%
Share Based Compensation	$ 1
Executives and Directors [Member] \| U.S.dollars [Member] \| Stock Option Grant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	9
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 20, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.05
Share Price	$ 2.43
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 5 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	147.00%
Share Based Compensation	$ 1

Stock options (Modification of Existing Canadian Dollar Denominated Options) (Details) - CAD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years	7 years
Executives and Directors [Member] \| Canadian dollars [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	665
Stock or Unit Option Plan Expense	$ 347
Executives and Directors [Member] \| Canadian dollars [Member] \| Stock Option Grant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	17
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 18, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.52%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.89
Share Price	$ 3.10
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 2 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	94.00%
Stock or Unit Option Plan Expense	$ 9
Executives and Directors [Member] \| Canadian dollars [Member] \| Stock Option Grant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	648
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 18, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.52%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.43
Share Price	$ 3.10
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 2 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	94.00%
Stock or Unit Option Plan Expense	$ 338

Stock options - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Apr. 25, 2014 shares	Jun. 24, 2010 shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2016 CAD ($)	Dec. 31, 2015 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value \| $			$ 575
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value \| $			3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value \| $			$ 280
Description of Difference between Reported Amount and Reporting Currency Denominated Amount			exchange rate of $CAD/$USD 0.7881	exchange rate of $CAD/$USD 0.7881
US Dollar Denominated Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms			the Company modified the terms of certain options granted to executives and directors by extending the expiration date by 1 year.	the Company modified the terms of certain options granted to executives and directors by extending the expiration date by 1 year.
Canadian Dollar Denominated Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms			Company modified the terms of certain options granted to executives and directors by extending the expiration date by a weighted average amount of 1.45 years.	Company modified the terms of certain options granted to executives and directors by extending the expiration date by a weighted average amount of 1.45 years.
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	133,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	66
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	67
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense \| $			$ 615		$ 97
General and Administrative Expense [Member] \| Executives and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock or Unit Option Plan Expense			$ 4	$ 347
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan		6,666
Percentage Of Total Number Of Share Issued and Outstanding		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares			$ 2.42		$ 1.37
Plan Maximum Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issuable under Stock Option Plan		3,410

Derivative Liabilities (Contractor Option Activity) (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Number of Options Outstanding and Exercisable at Ending	1,428
Derivative Instrument Option Activity [Member]
Number of Options Outstanding and Exercisable at Beginning	40	55
Number of Options Exercised	0	(14)
Number of Options Forfeited or expired	0	(1)
Number of Options Outstanding and Exercisable at Ending	40	40
Weighted-average Exercise Price Outstanding and Exercisable at Beginning	$ 1.81	$ 1.84
Weighted-average Exercise Price Exercised	0	1.94
Weighted-average Exercise Price Forfeited or expired	0	1.82
Weighted-average Exercise Price Outstanding and Exercisable at Ending	$ 1.81	$ 1.81

Derivative Liabilities (fair value liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Derivative Liability	$ 33	$ 82
Unrealized Gain (Loss) on Derivatives	48	1,237
Warrant on April 30, 2015 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	0	0
Unrealized Gain (Loss) on Derivatives	0	411
Warrant on March 29, 2016 [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	0	41
Unrealized Gain (Loss) on Derivatives	41	748
Options [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	33	41
Unrealized Gain (Loss) on Derivatives	$ 7	$ 78

Derivative Liabilities - Additional Information (Details) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)	Dec. 31, 2016 $ / shares	Dec. 31, 2011 shares	Dec. 31, 2010 shares
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,383
Derivative Liability \| $	$ 33	$ 82
Unrealized (loss)/gain on derivatives \| $	$ 48	1,237
Invester Option [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	40
Options Held [Member]
Derivative [Line Items]
Derivative Liability \| $	$ 33	41
Options to Contractors [Member]
Derivative [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				36	29
Unrealized (loss)/gain on derivatives \| $	$ 7	$ 78
Contractor Options Expire On November 19, 2017 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	21
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.89
Contractor Options Expire On April 4, 2018 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	17
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			1.62
Contractor Options Expire On May 18, 2018 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	2
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 2.43

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details)
$ in Thousands

Dec. 31, 2016

USD ($)

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

$ 3,926

Derivative liabilities

Quoted Price in Active Markets for Identical Instruments Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

^[1]

Derivative liabilities

Significant Other Observable Inputs Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

3,858

Derivative liabilities

Significant Unobservable Inputs Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

$ 0

[1]	The Company held $68 in cash, of which $51 was in Canadian funds (translated into U.S. dollars).

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Parenthetical) (Details) - 12 months ended Dec. 31, 2016 $ in Thousands, $ in Thousands	USD ($)	CAD ($)
Assumptions used to Determine Fair Value Options [Line Items]
Cash	$ 51	$ 68
Warrant [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Employee Stock Option [Member] \| Minimum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	0.33%
Expected volatility rate	57.00%
Expected life	10 months 24 days
Employee Stock Option [Member] \| Maximum [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Risk free interest rate	0.74%
Expected volatility rate	85.00%
Expected life	1 year 4 months 24 days

Stockholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details)
shares in Thousands

12 Months Ended

Dec. 31, 2016

$ / shares

Class of Warrant or Right [Line Items]

Common shares issuable upon exercise of outstanding warrants

1,383

Inverstor warrants one

Class of Warrant or Right [Line Items]

Common shares issuable upon exercise of outstanding warrants

1,333

^[1]

Exercise price in CAD/USD Dollars | $ / shares

$ 1.50

^[1]

Expiration Date

Nov. 22, 2018

^[1]

Investor warrants two

Class of Warrant or Right [Line Items]

Common shares issuable upon exercise of outstanding warrants

^[2]

Exercise price in CAD/USD Dollars | $ / shares

$ 3.00

^[2]

Expiration Date

Feb. 02, 2019

^[2]

[1]

[2]

Stockholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Feb. 02, 2016	May 16, 2016	Nov. 22, 2013	Dec. 31, 2016	Sep. 03, 2014
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants				(1,383,000)
Aranea Partners [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right ,Warrants Issued	50,000
Class Of warrant Or Right , Warrants Redeemable Price				$ 3.00
Private Placement [Member]
Class of Warrant or Right [Line Items]
Issuance of stock		2,631,579
Issuance of stock, price per share		$ 1.90
Proceeds from issuance of unit		$ 5,000,000
Equity Issuance Shares Issued		1,000
Nonbroker Rights [Member]
Class of Warrant or Right [Line Items]
Issuance of stock			4,000,000
Issuance of stock, price per share			$ 0.40
Proceeds from issuance of unit			$ 1,600
Common shares issuable upon exercise of outstanding warrants					(3,000)
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50		$ 1.50

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	May 16, 2016	Dec. 31, 2016
U.S.dollars [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.55
Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms		1 year 10 months 24 days
Private Placement [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues	2,631,579
Proceeds From Issuance Of Private Placement	$ 5,000
Equity Issuance Per Share Amounts	$ 1.90

Sale of Asset - Additional Information (Details) $ in Thousands	1 Months Ended
	Aug. 29, 2016 USD ($)
Proceeds from Sale of Property, Plant, and Equipment	$ 40
Disposal Of Asset Percentage Of Revenue Sharing	5.00%

Commitments and Contingencies - Additional information (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Rostislav Raykov
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 250
Chief Financial Officer [Member] \| Terminated After April 30, 2016 [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 95

De-recognition of Statute Barred Payables - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Derecognized Of Payable, Reversed Into Expenses	$ 79
General and Administrative Expense [Member]
Derecognized Of Payable, Reversed Into Expenses	23
Research and Development Expense [Member]
Derecognized Of Payable, Reversed Into Expenses	$ 56

Income Taxes (Canadian federal and provincial income tax rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Effective Tax Rate [Line Items]
Domestic (loss)/gain	$ (1,771)	$ 294
Foreign loss	(1,018)	(952)
Loss before income taxes	$ (2,789)	$ (658)
Expected statutory rate (recovery)	26.50%	26.50%
Expected provision for (recovery of) income tax	$ (739)	$ (174)
Permanent differences	156	(301)
Change in valuation allowance	583	(1,297)
Effect of foreign exchange rate differences	0	0
Effect of non-capital losses expired	0	1,318
Tax credits and other adjustments	1	450
Effect of tax rate changes and other	(1)	4
Provision for income taxes	$ 0	$ 0

Income Taxes (Future Income Taxes (Recovery)) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 23,592	$ 23,010
Less: valuation allowance	(23,592)	(23,010)
Net future tax assets	0	0
SR & ED expenditures [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	2,195	2,195
Income tax loss carryforwards [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	19,098	18,509
Non-refundable investment tax credits [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,263	1,263
Share issue costs [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	4	10
Accrued expenses [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	0	0
Fixed and intangible assets [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	1,032	1,032
Harmonization credit [Member]
Income Taxes Future Recovery Disclosure [Line Items]
Future tax assets gross	$ 0	$ 0

Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Federal [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	$ 8,283
Federal [Member] \| Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	26
Investment tax credits (expiry date)	55
Federal [Member] \| Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	233
Investment tax credits (expiry date)	548
Federal [Member] \| Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	133
Investment tax credits (expiry date)	399
Federal [Member] \| Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,536
Investment tax credits (expiry date)	178
Federal [Member] \| Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,795
Investment tax credits (expiry date)	199
Federal [Member] \| Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	20,562
Investment tax credits (expiry date)	86
Federal [Member] \| Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,340
Investment tax credits (expiry date)	90
Federal [Member] \| Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	10,840
Investment tax credits (expiry date)	50
Federal [Member] \| Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	8,502
Investment tax credits (expiry date)	0
Federal [Member] \| Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,608
Investment tax credits (expiry date)	0
Federal [Member] \| Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,378
Federal [Member] \| Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,491
Federal [Member] \| Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,788
Federal [Member] \| Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,812
Federal [Member] \| Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,803
Federal [Member] \| Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,222
Federal [Member] \| Year 2018 [Member]
Income Tax [Line Items]
Investment tax credits (expiry date)	10
Federal [Member] \| Year 2019 [Member]
Income Tax [Line Items]
Investment tax credits (expiry date)	8
Federal [Member] \| Year 2020 [Member]
Income Tax [Line Items]
Investment tax credits (expiry date)	96
Province State [Member]
Income Tax [Line Items]
SR & ED expenditures (no expiry)	0
Province State [Member] \| Year 2021 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| Year 2022 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| Year 2023 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	0
Province State [Member] \| Year 2024 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,455
Province State [Member] \| Year 2025 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	4,768
Province State [Member] \| Year 2026 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	12,945
Province State [Member] \| Year 2027 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	10,866
Province State [Member] \| Year 2028 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	10,550
Province State [Member] \| Year 2029 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,915
Province State [Member] \| Year 2030 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,243
Province State [Member] \| Year 2031 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	3,675
Province State [Member] \| Year 2032 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,754
Province State [Member] \| Year 2033 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,781
Province State [Member] \| Year 2034 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	1,684
Province State [Member] \| Year 2035 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	2,150
Province State [Member] \| Year 2036 [Member]
Income Tax [Line Items]
Income tax loss carryforwards (expiry date)	$ 1,013

Income Taxes - Additional Information (Details)	12 Months Ended
Income Taxes - Additional Information (Details)	Dec. 31, 2016
Canadian Statutory Income Tax [Member]
Income Taxes Disclosure - Additional Information [Line Items]
IncomeTax Rate	26.00%
Federal Income Tax [Member]
Income Taxes Disclosure - Additional Information [Line Items]
IncomeTax Rate	15.00%
Provincial Income Tax [Member]
Income Taxes Disclosure - Additional Information [Line Items]
IncomeTax Rate	11.00%